| 利妥昔单抗联合CHOP方案治疗NHL的临床疗效评价 |
| |
| 引用本文： | 郭俊煜,石浩强,张芬琴.利妥昔单抗联合CHOP方案治疗NHL的临床疗效评价[J].中国药房,2007,18(26):2042-2043. |
| |
| 作者姓名： | 郭俊煜 石浩强 张芬琴 |
| |
| 作者单位： | 1. 上海市医药股份有限公司,上海市,200002
2. 上海市瑞金医院,上海市,200025 |
| |
| 摘 要： | 目的:探讨利妥昔单抗联合环磷酰胺、阿霉素、长春新碱、强的松(CHOP)方案治疗非霍奇金淋巴瘤(NHL)的疗效及安全性。方法:62例NHL患者,其中32例接受利妥昔单抗联合CHOP方案治疗者为治疗组;30例接受CHOP方案治疗者为对照组。每周期21d,共进行6个疗程。结果:治疗组与对照组总有效率分别为75.00%、60.00%(P<0.05);2组毒副作用基本相似(P>0.05);治疗组的生活质量改善情况明显高于对照组(P<0.05)。结论:利妥昔单抗联合CHOP方案对NHL患者有较好疗效,且化疗药物的毒副作用未见增加。
|
| 关 键 词： | 非霍奇金淋巴瘤 利妥昔单抗 CHOP 治疗 |
| 文章编号： | 1001-0408（2007）26-2042-02 |
| 收稿时间： | 2007-08-17 |
| 修稿时间： | 2007-08-20 |
Rituximab in Combination with CHOP Scheme for Non - Hodgkin's Lymphoma: Evaluation of Clinical Efficacy |
| |
| GUO Junyu,SHI Haoqiang,ZHANG Fenqin.Rituximab in Combination with CHOP Scheme for Non - Hodgkin''''s Lymphoma: Evaluation of Clinical Efficacy[J].China Pharmacy,2007,18(26):2042-2043. |
| |
| Authors: | GUO Junyu SHI Haoqiang ZHANG Fenqin |
| |
| Institution: | 1Shanghai Pharmaceutical Co. Ltd., Shanghai 200002, China;2Shanghai Ruijin Hospital, Shanghai 200025, China |
| |
| Abstract: | OBJECTIVE: To study the efficacy and safety of rituximab in combination with CHOP scheme in treating Non-Hodgkin' s Lymphoma.METHODS: A total of 62 NHL patients were enrolled and randomly assigned to trial group(rituximab CHOP,n=32) or control group(CHOP,n=30).Each course of treatment lasted for 21 days for a total of 6 courses of treatment.RESULTS: The total effective rates of trial group vs.control group were 75.00% vs.60.00%(P<0.05).The toxicity in the two groups was similar and tolerated(P>0.05).The quality of life in the trial group had a better improvement than in the control group(P<0.05).CONCLUSION: Rituximab in combination with CHOP scheme showed a satisfactory efficay for Non-Hodgkin' s Lymphoma,and the toxicity of the chemotherapeutics had no increase. |
| |
| Keywords: | CHOP |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
